Disparity In Beta Blocker Prescription In Heart Failure
Ronaldo Correa Fabiano Filho,Joseph Ibrahim,Floyd Thoma,Samir Saba,Gavin Hickey
DOI: https://doi.org/10.1016/j.cardfail.2023.10.425
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Beta-blockers (BB) have been shown to reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF). Despite guideline recommendations by ACC/AHA many HFrEF patients are not prescribed BB therapy. We aimed to identify factors associated with lack of BB use in a HFrEF cohort. Methods Patients with left ventricular ejection fraction (LVEF) ≤40% and new diagnosis of HFrEF at University of Pittsburgh Medical Center Hospital System between January 1, 2011, and December 31, 2017 were included. Exclusion criteria were prior cardiac arrest or ventricular arrhythmia. Patients were followed from first outpatient visit until March 24, 2019. Patients were stratified into two groups based on BB use in first 6 months after diagnosis. Clinical, demographic, and laboratory data were stratified and compared between these groups. Variables were treated as categorical or continuous and parametric/nonparametric tests were used as appropriate. Analyses were performed with Stata 17.0. Results In our cohort of 17,064 patients, BB was prescribed in 85% (14,503/17,064). Using only complete data during the follow-up period, 7.7% (1,265/16,365) were never prescribed BB therapy. Median cohort follow-up was 1286 days (IQR 587-1923). Significant differences were seen between no BB use vs BB use respectively for age (68.4±15.9 vs 70.3±13.8; p<.01), female (15.7% vs 84.3%, p=.03), cardiac resynchronization therapy device implant (22.2% vs 77.8%, p<.01), body mass index (28.1±6.9 vs 29.1±6.7, p<.01), hypertension (12.3% vs 87.7%, p<.01), diabetes mellitus (10.6% vs 89.4%, p<.01), chronic obstructive pulmonary disease (16.5% vs 83.5%, p=.02), vascular disease [coronary (9.9% vs 90.1%, p<.01), peripheral (9.2% vs 90.8%, p<.01), ischemic stroke (12.5% vs 87.5%, p<.01)], atrial fibrillation (12% vs 88%, p<.01), and chronic kidney disease (9.2% vs 90.8%, p<.01). Conclusion Despite known benefits, many patients with HFrEF are not prescribed BB therapy. We found significant age, gender, and clinical discrepancies between patients with HFrEF who were and were not prescribed BB therapy. Overall, the BB use group was older, predominantly male, with a higher frequency of comorbidities. Further investigation is necessary to determine potential reasons for this difference and if there are differences in outcomes between them after adjustment for unbalanced baseline covariates.
cardiac & cardiovascular systems